Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.
News and Features
Sparsentan is an endothelin and angiotensin II receptor antagonist.
Improvement seen in median imaging-based progression-free survival, regardless of homologous recombination repair status
Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, and opioid misuse, investigators noted.
Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted.
Increases seen in brain processing, penile tumescence, and behavioral measures of sexual desire and arousal
Significant negative impacts seen on activity, productivity, cost, and health-related quality of life
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
Authors say the new algorithm could be used to safely withhold antibiotics in low-risk patients in the primary care setting
The two cases do not appear to have a direct connection to each other
A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and novel biologic agents.
The approval was based on data from a phase 3 trial in adults with BCG-unresponsive, high-risk, NMIBC with CIS with or without papillary tumors following transurethral resection.
Several factors were associated with an increased risk of UTI recurrence. These included antibiotic exposure prior to treatment, pyelonephritis on diagnosis date, having a follow-up visit during antibiotic treatment, receiving parenteral antibiotics.
A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
In second study, plazomicin may be beneficial for carbapenem-resistant Enterobacteriaceae infections